National Institutes of Health (NIH)

313 articles about National Institutes of Health (NIH)

• VillageMD Selected for New NIH-Funded Study to Identify Undiagnosed Alzheimer’s Disease and Related Dementias

  6/6/2023

  VillageMD Research Institute is one of three site collaborators selected to participate in a two-year study led by Together Senior Health and University of California San Francisco.

• Sensydia Secures $3M NIH Grant to Advance AI-Based Cardiac Assessment Platform

  6/5/2023

  Non-invasive cardiac diagnostic company Sensydia announced that it was awarded a Fast-Track Small Business grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

• CND Life Sciences' Syn-One Test® Detects Alpha-Synuclein in the Skin with High Sensitivity and Specificity in Patients with Parkinson's Disease and Related Disorders

  4/26/2023

  CND Life Sciences, a medical technology company pioneering the development of cutaneous neurodiagnostics, announced topline results from its landmark Synuclein-One Study sponsored by the National Institutes of Health.

• NIH Awards $4.7M to Cohen Children’s Medical Center, Feinstein Institutes to Study Nephrotic Syndrome in Children

  4/5/2023

  The National Institutes of Health has awarded Northwell Health’s Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research, the homes of pediatric research at Northwell, two grants totaling $4.73 million to study nephrotic syndrome – a kidney disorder that causes the body to pass too much protein into the urine – specifically in children.

• Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

  3/21/2023

  Disc Medicine, Inc. announced a collaboration with the National Heart Lung and Blood Institute of the National Institutes of Health to evaluate bitopertin, a therapeutic candidate designed to modulate heme biosynthesis, in a phase 2 clinical study of patients with Diamond-Blackfan anemia.

• Team Aims to Transform Care for Diffuse Intrinsic Pontine Glioma

  2/22/2023

  Researchers at Children’s Hospital Los Angeles have received a nearly $1 million K08 grant from the National Institutes of Health —as well as funding from the U.S. Department of Defense—to support studies into diffuse intrinsic pontine glioma, a childhood brain tumor with a 0% survival rate.

• NeoImmuneTech to Partner with U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for Drug Development in Acute Radiation Syndrome (ARS)

  1/3/2023

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced an agreement with the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, to develop NeoImmuneTech's main asset NT-I7, for the treatment of Acute Radiation Syndrome.

• Albert Einstein College of Medicine and Montefiore Health System Receive $5.2 Million NIH Grant to Study Heart Failure in Hispanic Populations

  12/15/2022

  Cardiology researchers at Albert Einstein College of Medicine and Montefiore Health System have received a five-year, $5.2 million grant from the National Institutes of Health to explore the underlying causes of heart failure among Hispanics/Latinos, who are at heightened risk for heart disease.

• Berkshire Biomedical Awarded Phase II Funding for NIH Research Grant to Support Continued Development of the COPA™ System for Automated at Home Methadone Administration

  12/7/2022

  Berkshire Biomedical Corporation today announced that it has been awarded the second phase of a two-phase Fast-Track Small Business Innovation Research (SBIR) grant (1R44DA057185-01) from the National Institutes of Health's (NIH) National Institute of Drug Abuse (NIDA).

• SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi

  11/30/2022

  SCYNEXIS, Inc. today announced that researchers from Case Western Reserve University in Cleveland have been awarded a competitive research grant of more than $3 million by the National Institutes of Health (NIH), to investigate a second generation fungerp (SCY-247).

• Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer

  11/29/2022

  Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer.

• Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy

  11/29/2022

  Turnstone Biologics Corp today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to evaluate the generation of tumor-reactive T-cells, which form the basis of Turnstone’s tumor-infiltrating lymphocyte platform.

• Spaulding Rehabilitation Hospital and Highland Instruments, Inc., Jointly Announce National Institutes of Health Funded Clinical Trial Investigating Highland's Electrosonic Stimulation Technology to Treat Carpal Tunnel Syndrome

  11/28/2022

  Spaulding Rehabilitation Hospital, a teaching affiliate of Harvard Medical School, and Highland Instruments, Inc., jointly announced the advancement into Phase II of their National Institutes of Health funded Clinical Trial investigating Highland Instruments' Electrosonic Stimulation, a novel noninvasive brain stimulation technology, to treat Carpal Tunnel Syndrome1.

• FIU wins $19.4M NIH grant to fight health disparities

  11/15/2022

  Florida International University researchers are at the forefront of ensuring the health and well-being of underserved communities don't slip through the cracks.

• ABL Awarded $Multimillion Contract to Provide Manufacturing and Nonclinical Services to Support Development of Promising Therapeutics for the NINDS

  11/4/2022

  Advanced BioScience Laboratories announced it is one of three contractors awarded an Indefinite Delivery, Indefinite Quantity contract for "Manufacturing and Nonclinical Studies support for Development of Therapeutic Biotechnology Products for Neurological-related Disorders" by the NINDS of the NIH of the HHS.

• ABL Awarded NIH Contract for Continued Support of HIV Vaccine Development

  10/20/2022

  Advanced BioScience Laboratories announced it has been awarded a contract for "Preclinical and translational vaccine development for HIV and other candidate agents" by the Division of AIDS within the National Institute of Allergy and Infectious Disease of the National Institutes of Health.

• Vivasc Therapeutics Inc. Receives Its Second NIH Phase I STTR Grant With the Goal of Reversing the Molecular Causes of Heart Failure

  10/19/2022

  Vivasc Therapeutics Inc. is pleased to announce it has initiated its second NIH Phase I STTR research grant, in conjunction with Georgetown University.

• Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program

  10/19/2022

  Trethera Corporation announced that the National Eye Institute, a division of the National Institutes of Health, has awarded Trethera a $1.6 million Fast-Track STTR commercialization grant to further develop TRE-515 as a treatment for optic neuritis.

• The FNIH Announces New Research Initiative to Identify More Precise Treatment Strategies for Patients Suffering from Heart Failure

  9/29/2022

  The Foundation for the National Institutes of Health and the National Heart Lung and Blood Institute at the National Institutes of Health are launching a new partnership to investigate the syndrome of heart failure with preserved ejection fraction.

• FDA and NIH Launch Public-Private Partnership for Rare Neurodegenerative Diseases

  9/14/2022

  Today, the U.S. Food and Drug Administration and the National Institutes of Health (NIH) announced the launch of the Critical Path for Rare Neurodegenerative Diseases (CP-RND).